WASHINGTON -- A blood-based test for the early detection of colorectal cancer (CRC) met its prespecified sensitivity and specificity endpoints, according to results from the PREEMPT CRC study. Using ...

The ctDNA test showed 79.2% sensitivity and 91.5% specificity for CRC detection in a diverse cohort. The study met primary end points but had limited sensitivity for advanced precancerous lesions.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Negative predictive value for nonadvanced colorectal ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. “More than three out of four Americans who die from ...

Although considered a single class, fecal immunochemical tests (FITs) vary in their ability to detect advanced colorectal neoplasia (ACN) and should not be considered interchangeable, new research ...

Two noninvasive screening tests appeared to be effective in detecting colorectal cancer in an average-risk population, two trials suggested. In the BLUE-C trial, a next-generation multi-target stool ...

In July, the US Food and Drug Administration (FDA) approved a new blood-based test to screen for colorectal cancer (CRC). The FDA's approval of Shield (Guardant Health) marks a notable achievement, as ...

Latest algorithm (Shield V2) has sensitivity of 84% for colorectal cancer with specificity of 90%, with stage I sensitivity of 62% Performance of the Shield algorithm was validated in expanded ...

Princeton University and collaborators have developed SHINE-TB, a one-sample, parallelized reaction amplification and detection CRISPR assay that detects Mycobacterium tuberculosis directly from ...

Conclusions The K-D has fair test-retest reliability. The combination of sensitivity and specificity with any increase in time is better than other currently used objective measures of concussion.